Bradley Pfeifer, MD
Family Medicine · Fremont, NENPI 1295316115
Payments from drug & device makers
Across 41 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$113
- Novo Nordisk$106
- AbbVie$89
- Lilly USA, LLC$66
- Vertex$56
- Pfizer$52
- plus $222 from 10 others
What the payments were for
- Food & beverage$704100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 7 | $113 |
| Novo Nordisk | 7 | $106 |
| AbbVie | 5 | $89 |
| Lilly USA, LLC | 4 | $66 |
| Vertex | 2 | $56 |
| Pfizer | 3 | $52 |
| AstraZeneca | 3 | $46 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Mirum Pharmaceuticals, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Ardelyx, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
How this compares
$704 in reported general payments places this provider in the 55th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 13 | $7,357 |
| Atorvastatin Calcium | 49 | $548 |
| Ipratropium Bromide | 15 | $419 |
| Omeprazole | 36 | $404 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 34 | $366 |
| Losartan Potassium | 23 | $345 |
| Lisinopril | 39 | $287 |
| Gabapentin | 15 | $209 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $198 |
| Levothyroxine Sodium | 22 | $140 |
| Alendronate Sodium | 13 | $133 |
| Allopurinol | 12 | $121 |
| Simvastatin | 16 | $111 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $66 |
| Amlodipine Besylate | 11 | $27 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Fremont
- Thomas WolfFremont$8.2M
- Matthew BeacomFremont$100K
- Thomas McKnightFremont$30K
- Andrea VermaasFremont$11K
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.